Trade Inozyme Pharma, Inc. - INZY CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024874% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.002651% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 0.99-6.25 |
| Average Volume (10 days) | 879.91K |
| Average Volume (3 months) | 31.22M |
| Market Cap | 191.06M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 43.72M |
| Revenue | N/A |
| EPS | -1.90 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | May 8, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Inozyme Pharma, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 68.675 | 56.646 | 57.041 | 20.806 | 11.593 |
| Selling/General/Admin. Expenses, Total | 20.826 | 18.926 | 10.548 | 4.586 | 3.494 |
| Research & Development | 47.849 | 37.72 | 46.493 | 16.22 | 8.099 |
| Operating Income | -68.675 | -56.646 | -57.041 | -20.806 | -11.593 |
| Interest Income (Expense), Net Non-Operating | 1.933 | 0.211 | 0.37 | 1.106 | 0.284 |
| Other, Net | -0.319 | -0.189 | 0.247 | -0.024 | 4.345 |
| Net Income Before Taxes | -67.061 | -56.624 | -56.424 | -19.724 | -6.964 |
| Net Income After Taxes | -67.061 | -56.624 | -56.424 | -19.724 | -6.964 |
| Net Income Before Extra. Items | -67.061 | -56.624 | -56.424 | -19.724 | -6.964 |
| Net Income | -67.061 | -56.624 | -56.424 | -19.724 | -6.964 |
| Income Available to Common Excl. Extra. Items | -67.061 | -56.624 | -56.424 | -19.724 | -6.964 |
| Income Available to Common Incl. Extra. Items | -67.061 | -56.624 | -56.424 | -19.724 | -6.964 |
| Diluted Net Income | -67.061 | -56.624 | -56.424 | -19.724 | -6.964 |
| Diluted Weighted Average Shares | 37.7632 | 23.5583 | 23.385 | 20.3148 | 20.3148 |
| Diluted EPS Excluding Extraordinary Items | -1.77583 | -2.40357 | -2.41283 | -0.97092 | -0.3428 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -1.77583 | -2.40357 | -2.41283 | -0.97092 | -0.3428 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 19.533 | 16.912 | 15.391 | 16.839 | 18.757 |
| Selling/General/Admin. Expenses, Total | 5.696 | 4.721 | 5.384 | 5.025 | 5.206 |
| Research & Development | 13.837 | 12.191 | 10.007 | 11.814 | 13.551 |
| Operating Income | -19.533 | -16.912 | -15.391 | -16.839 | -18.757 |
| Interest Income (Expense), Net Non-Operating | 0.815 | 0.737 | 0.321 | 0.06 | 0.043 |
| Other, Net | 0.174 | -0.197 | -0.191 | -0.105 | -0.04 |
| Net Income Before Taxes | -18.544 | -16.372 | -15.261 | -16.884 | -18.754 |
| Net Income After Taxes | -18.544 | -16.372 | -15.261 | -16.884 | -18.754 |
| Net Income Before Extra. Items | -18.544 | -16.372 | -15.261 | -16.884 | -18.754 |
| Net Income | -18.544 | -16.372 | -15.261 | -16.884 | -18.754 |
| Income Available to Common Excl. Extra. Items | -18.544 | -16.372 | -15.261 | -16.884 | -18.754 |
| Income Available to Common Incl. Extra. Items | -18.544 | -16.372 | -15.261 | -16.884 | -18.754 |
| Diluted Net Income | -18.544 | -16.372 | -15.261 | -16.884 | -18.754 |
| Diluted Weighted Average Shares | 43.7856 | 43.6577 | 39.7035 | 23.6863 | 23.6673 |
| Diluted EPS Excluding Extraordinary Items | -0.42352 | -0.37501 | -0.38437 | -0.71282 | -0.7924 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Diluted Normalized EPS | -0.42352 | -0.37501 | -0.38437 | -0.71282 | -0.7924 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total Current Assets | 115.342 | 150.979 | 47.46 | 43.267 |
| Cash and Short Term Investments | 111.801 | 147.697 | 47.132 | 43.163 |
| Cash & Equivalents | 23.316 | 28.04 | 31.605 | 35.966 |
| Short Term Investments | 88.485 | 119.657 | 15.527 | 7.197 |
| Total Receivables, Net | 0.062 | 0.155 | 0.104 | 0.031 |
| Prepaid Expenses | 3.479 | 3.127 | 0.224 | 0.073 |
| Total Assets | 123.541 | 169.363 | 47.944 | 43.543 |
| Property/Plant/Equipment, Total - Net | 4.436 | 2.648 | 0.298 | 0.242 |
| Property/Plant/Equipment, Total - Gross | 5.437 | 2.975 | 0.408 | 0.269 |
| Accumulated Depreciation, Total | -1.001 | -0.327 | -0.11 | -0.027 |
| Other Long Term Assets, Total | 3.763 | 3.537 | 0.186 | 0.034 |
| Total Current Liabilities | 11.633 | 9.973 | 3.236 | 2.389 |
| Accounts Payable | 2.394 | 3.069 | 0.901 | 0.984 |
| Accrued Expenses | 9.239 | 6.625 | 2.335 | 1.405 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.273 | 11.26 | 3.236 | 2.389 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Total Equity | 109.268 | 158.103 | 44.708 | 41.154 |
| Preferred Stock - Non Redeemable, Net | 77.927 | 55.029 | ||
| Common Stock | 0.002 | 0.002 | 0.001 | 0.001 |
| Additional Paid-In Capital | 256.948 | 249.175 | 1.427 | 1.054 |
| Retained Earnings (Accumulated Deficit) | -147.7 | -91.076 | -34.652 | -14.928 |
| Other Equity, Total | 0.018 | 0.002 | 0.005 | -0.002 |
| Total Liabilities & Shareholders’ Equity | 123.541 | 169.363 | 47.944 | 43.543 |
| Total Common Shares Outstanding | 23.6726 | 23.385 | 20.3148 | 20.3148 |
| Total Preferred Shares Outstanding | 72.4164 | |||
| Long Term Investments | 0 | 12.199 | ||
| Other Current Liabilities, Total | 0 | 0.279 | ||
| Other Liabilities, Total | 2.64 | 1.287 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 100.583 | 115.342 | 130.579 | 140.962 | 148.041 |
| Cash and Short Term Investments | 97.773 | 111.801 | 125.283 | 137.464 | 145.086 |
| Cash & Equivalents | 31.943 | 23.316 | 27.229 | 26.239 | 16.486 |
| Short Term Investments | 65.83 | 88.485 | 98.054 | 111.225 | 128.6 |
| Total Receivables, Net | 0.048 | 0.062 | 0.073 | 0.095 | 0.122 |
| Prepaid Expenses | 2.762 | 3.479 | 5.223 | 3.403 | 2.833 |
| Total Assets | 108.931 | 123.541 | 137.746 | 148.259 | 158.915 |
| Property/Plant/Equipment, Total - Net | 4.184 | 4.436 | 4.743 | 4.859 | 5.029 |
| Property/Plant/Equipment, Total - Gross | 5.363 | 5.437 | 5.562 | 5.511 | 5.514 |
| Accumulated Depreciation, Total | -1.179 | -1.001 | -0.819 | -0.652 | -0.485 |
| Long Term Investments | 0 | 0 | 0 | 2.548 | |
| Other Long Term Assets, Total | 4.164 | 3.763 | 2.424 | 2.438 | 3.297 |
| Total Current Liabilities | 12.26 | 11.633 | 8.943 | 6.972 | 6.832 |
| Accounts Payable | 2.2 | 2.394 | 0.626 | 0.796 | 1.709 |
| Accrued Expenses | 10.06 | 9.239 | 8.317 | 6.176 | 5.123 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.702 | 14.273 | 11.772 | 9.985 | 10.026 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 2.442 | 2.64 | 2.829 | 3.013 | 3.194 |
| Total Equity | 94.229 | 109.268 | 125.974 | 138.274 | 148.889 |
| Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
| Additional Paid-In Capital | 258.94 | 256.948 | 254.915 | 252.92 | 251.001 |
| Retained Earnings (Accumulated Deficit) | -164.584 | -147.7 | -128.946 | -114.666 | -102.126 |
| Other Equity, Total | -0.129 | 0.018 | 0.003 | 0.018 | 0.012 |
| Total Liabilities & Shareholders’ Equity | 108.931 | 123.541 | 137.746 | 148.259 | 158.915 |
| Total Common Shares Outstanding | 23.8184 | 23.6726 | 23.6647 | 23.5706 | 23.4737 |
| Other Current Liabilities, Total | 0 | 0 | 0 | ||
| Preferred Stock - Non Redeemable, Net | 0 | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Net income/Starting Line | -56.624 | -56.424 | -19.724 | -6.964 |
| Cash From Operating Activities | -48.153 | -35.974 | -18.81 | -9.437 |
| Cash From Operating Activities | 0.674 | 0.217 | 0.083 | 0.026 |
| Non-Cash Items | 7.712 | 20.344 | 0.23 | -3.93 |
| Changes in Working Capital | 0.085 | -0.111 | 0.601 | 1.431 |
| Cash From Investing Activities | 42.796 | -117.179 | -8.391 | 9.006 |
| Capital Expenditures | -0.397 | -0.568 | -0.139 | -0.259 |
| Other Investing Cash Flow Items, Total | 43.193 | -116.611 | -8.252 | 9.265 |
| Cash From Financing Activities | 0.609 | 149.812 | 22.97 | 31.945 |
| Issuance (Retirement) of Stock, Net | 0.609 | 149.812 | 22.97 | 31.945 |
| Net Change in Cash | -4.724 | -3.341 | -4.231 | 31.514 |
| Foreign Exchange Effects | 0.024 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.884 | -56.624 | -37.87 | -23.59 | -11.05 |
| Cash From Operating Activities | -14.16 | -48.153 | -34.709 | -22.409 | -12.376 |
| Cash From Operating Activities | 0.178 | 0.674 | 0.492 | 0.325 | 0.158 |
| Non-Cash Items | 1.779 | 7.712 | 5.567 | 3.689 | 1.725 |
| Changes in Working Capital | 0.767 | 0.085 | -2.898 | -2.833 | -3.209 |
| Cash From Investing Activities | 22.562 | 42.796 | 33.309 | 20.247 | 0.573 |
| Capital Expenditures | -0.017 | -0.397 | -0.357 | -0.278 | -0.088 |
| Other Investing Cash Flow Items, Total | 22.579 | 43.193 | 33.666 | 20.525 | 0.661 |
| Cash From Financing Activities | 0.24 | 0.609 | 0.598 | 0.361 | 0.249 |
| Issuance (Retirement) of Stock, Net | 0.24 | 0.609 | 0.598 | 0.361 | 0.249 |
| Net Change in Cash | 8.627 | -4.724 | -0.811 | -1.801 | -11.554 |
| Foreign Exchange Effects | -0.015 | 0.024 | -0.009 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Longitude Capital Management Co., LLC | Venture Capital | 9.548 | 4174379 | 1355000 | 2022-04-19 | LOW |
| Sofinnova Investments, Inc | Venture Capital | 8.3607 | 3655308 | 0 | 2022-12-31 | MED |
| Deep Track Capital LP | Hedge Fund | 7.4337 | 3250000 | 0 | 2022-12-31 | MED |
| Adage Capital Management, L.P. | Hedge Fund | 7.0909 | 3100138 | 503466 | 2022-12-31 | LOW |
| Rock Springs Capital Management LP | Hedge Fund | 7.0586 | 3086027 | 278409 | 2022-12-31 | LOW |
| VR Adviser, LLC | Venture Capital | 6.1985 | 2709987 | 0 | 2022-12-31 | MED |
| Pivotal Bioventure Partners Investment Advisor LLC | Investment Advisor | 6.0868 | 2661154 | 0 | 2022-12-31 | LOW |
| New Enterprise Associates (NEA) | Venture Capital | 5.5757 | 2437689 | -6690 | 2022-12-31 | LOW |
| Cowen Investment Management LLC | Investment Advisor/Hedge Fund | 5.0432 | 2204876 | 208599 | 2022-12-31 | MED |
| Sphera Funds Management Ltd. | Hedge Fund | 4.7947 | 2096258 | 471200 | 2023-03-03 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.0732 | 1343622 | 559 | 2022-12-31 | LOW |
| Affinity Asset Advisors LLC | Hedge Fund | 1.1436 | 500000 | 500000 | 2022-12-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.6815 | 297936 | 127752 | 2022-12-31 | HIGH |
| Laurion Capital Management LP | Hedge Fund | 0.6217 | 271800 | 0 | 2022-12-31 | HIGH |
| Bolte (Axel) | Individual Investor | 0.599 | 261890 | 3315 | 2022-09-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.5922 | 258900 | 103500 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.5878 | 256970 | -1351 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5332 | 233126 | -559 | 2022-12-31 | LOW |
| BioImpact Capital LLC | Investment Advisor/Hedge Fund | 0.5272 | 230500 | -430644 | 2022-12-31 | LOW |
| Overbrook Management Corporation | Investment Advisor | 0.5017 | 219326 | 150000 | 2022-12-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Inozyme Pharma, Inc. Company profile
About Inozyme Pharma Inc
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Inozyme Pharma Inc revenues was not reported. Net loss decreased less than 1% to $56.6M. Net income also reflects Research and development decrease of 19% to $37.7M (expense), offset by General and administrative increase of 79% to $18.9M (expense), Other income (expenses) decrease from $247K (income) to $189K (expense), Interest income decrease of 43% to $211K (income).
| Industry: | Biotechnology & Medical Research (NEC) |
321 Summer Street
Suite 400
02210
Income Statement
- Annual
- Quarterly
News
PRECIOUS-Gold pares gains as higher yields limit dollar support
Gold prices pared earlier gains on Thursday as higher bond yields dulled bullion's shine, limiting the upside from a weaker dollar as investors waited for U.S. inflation data to gauge the Federal Reserve's next move.
14:33, 30 March 2023
Bed Bath & Beyond announces $300 mln stock offering
Bed Bath & Beyond Inc said on Thursday it has reached an agreement with investment bank B Riley to sell $300 million of its shares, as the struggling retailer looks to raise equity.
14:32, 30 March 2023
U.S. weekly jobless claims still low; corporate profits fall in Q4
The number of Americans filing new claims for unemployment benefits rose moderately last week, showing no signs yet that tightening credit conditions were having a material impact on the tight labor market.
14:29, 30 March 2023
US STOCKS-Wall St gains as bank fears fade, focus on inflation data
Wall Street's main indexes climbed on Thursday as fears of a banking crisis eased, with rate-sensitive realty and technology stocks leading gains ahead of key inflation data that could shape the Federal Reserve's policy path.
14:11, 30 March 2023
South African rand firms after central bank rate surprise
South Africa's rand strengthened against the dollar on Thursday after the central bank raised its main interest rate by a higher than forecast 50 basis points to 7.75%.
14:10, 30 March 2023
South Africa raises key lending rate higher than expected to 7.75%
South Africa's central bank raised its main lending rate by a higher than expected 50 basis points to 7.75% in a decision announced on Thursday.
13:38, 30 March 2023
BUZZ-COMMENT-EUR/USD bulls now look for US PCE to intensify tail winds
EUR/USD struck a 5-session high Thursday with help from German inflation data and interest rate spreads, and longs now hope U.S. February PCE, the Fed's favorite pricing indicator, can reinforce the upward momentum.
13:38, 30 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com